Objectives: The present 12-week, open-label uncontrolled trial was aimed to explore the efficacy of ziprasidone add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of patients with treatment-resistant obsessive-compulsive disorder receiving serotonin reuptake inhibitors (SRIs).
O bsessive-compulsive disorder (OCD) is a chronic and disabling disorder with a lifetime prevalence of 2% to 3%, characterized by early-onset and commonly unremitting course persisting into adulthood. 1 It significantly affects quality of life and several other domains, such as social functioning, the ability to study and work, and interpersonal relationships. 2 Serotonin reuptake inhibitors (SRIs), which include clomipramine and selective serotonin reuptake inhibitors (SSRIs), at the maximum-tolerated doses for at least 8 to 12 weeks, are considered first-line pharmacological treatments for patients OCD. 3 Nevertheless, it has been estimated that approximately 40% to 60% of OCD patients do not respond adequately to an initial SRI treatment, 4, 5 and only a very small proportion of adults with OCD achieve clinical remission over the long term. 6 In clinical practice, treatment options for patients who partially respond to SRIs include increasing the dose and duration of pharmacotherapy, switching to a different drug, combining medications from the same drug class, augmenting a first drug with a second agent from a different drug class, and finally using novel agent strategies. 7 Augmentation strategies have evaluated the effect of mood stabilizers, such as lamotrigine, 8 topiramate, 9 and pregabalin 10 ; preliminary results show that more evidence is required to recommend their routine use as augmenting agents. Results of available studies provide evidence that augmentation with atypical antipsychotics appears to be a useful treatment strategy. 11, 12 Antipsychotics have been proposed as add-on therapy to SSRIs in 4 OCD subtypes: OCD with poor insight; refractory OCD, where the definition of refractoriness requires 3 months of maximal monotherapy treatment with a SSRI; OCD with tics; and OCD comorbid with schizophrenia. 13 Positive evidence exists for risperidone, olanzapine, quetiapine, aripiprazole, and amisulpride. [14] [15] [16] [17] [18] Ziprasidone is an atypical antipsychotic drug acting as an antagonist of both the 5-hydroxytryptamine-2A (5-HT2A) and dopamine 2 (D2) receptors, with an 8-fold greater affinity for the 5-HT2A receptor than the D2 receptor; the serotonin/dopamine ratio is one of the highest among the atypical antipsychotics. It is also a strong 5-HT1D antagonist and 5-HT1A agonist; it binds with moderate potency to the histamine-1 and α1-adrenergic receptors, and its affinity for muscarinic-1 receptor is negligible. The peculiar profile of ziprasidone is consistent with antipsychotic activity associated with a decreased risk of extrapyramidal side effects, a weight neutral profile, and the potential for both antidepressant and anxiolytic activity. 19 Evidence concerning the use of ziprasidone as an augmenting agent in OCD treatment is still sparse. In a 4-week case report of a female patient with OCD who previously failed to respond to SSRIs, ziprasidone at the daily dose of 40 mg added to ongoing treatment improved the OC symptoms, as documented by the significant decrease in Yale-Brown Obsessive Compulsive Scale (Y-BOCS). 20 A retrospective study has compared the efficacy of quetiapine up to 1200 mg/d (n = 15) or ziprasidone up to 160 mg/d (n = 9) in 24 patients affected by treatment-resistant OCD without psychotic features; ziprasidone was less effective than quetiapine, with only 44.4% of ziprasidone-treated patients showing clinical improvement. 21 Furthermore, the efficacy of ziprasidone augmentation for OC symptoms in schizophrenia has been evaluated in a case series 22 and in a recent open prospective study, 23 with conflicting results.
On the basis of evidence from the literature, the present study was aimed to explore the efficacy and safety of ziprasidone addon pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients.
MATERIALS AND METHODS

Subjects
The study was carried out at the Psychiatry Unit of the University Hospital of Messina, Messina, Italy. Outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for OCD and demonstrated persistent OC symptoms despite an adequate trial with an SRI for at least 12 weeks were considered for an augmentation trial with ziprasidone.
Eligible subjects had to have a Y-BOCS total score of 16 or greater. 24, 25 All patients received a diagnosis of OCD as their primary disorder by a senior psychiatrist using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I disorders. 26 Dosages of SRIs had been stable for at least 2 months before the study and were left unchanged throughout the study. During the study, no additional medications were allowed. Patients with any other major psychiatric disorder, significant concurrent medical illnesses, organic brain disorder, history of substance and alcohol abuse, mental retardation, pregnant or lactating women, or those with baseline QTc (using Bazett correction) greater than 450 milliseconds were excluded. Patients were also excluded if they received concomitant specific psychotherapies.
All the patients provided written informed consent after a full explanation of the protocol design, which had been approved by the local ethics committee (protocol E 71/11, November 25, 2011) and was conducted according to the Declaration of Helsinki.
Study Design
This trial was a 12-week, open-label, uncontrolled trial of adjunctive ziprasidone to SRI therapy in OCD. Ziprasidone was administered at the dose of 80 mg/d and was maintained unchanged until the end of the trial at week 12.
Treatment response was measured by the change from baseline to final value at week 12 of the study. The following instruments were used as primary efficacy measures: Y-BOCS, 24, 25 and Hamilton Rating Scale for Depression. 27 Response to ziprasidone was defined as clinical improvement in the OC component (>25% decrease in the total Y-BOCS score).
Neurocognitive functioning was assessed with the Wisconsin Card Sorting Test, 28 the Stroop Colour-Word Test, 29 and the Trail Making Test. 30 Both clinical ratings and neurocognitive tasks were administered by psychiatrists with at least 5 years of experience in the treatment of anxiety and mood disorders and trained in the use of neuropsychological instruments.
Patients attended 5 visits: initial screening (week −1), inclusion (week 0), and 3 further visits at weeks 4, 8, and 12. Data for clinical and neurocognitive assessments were collected at weeks 0 and 12; the design of interest intervals has been chosen with the aim of reducing possible sources of bias, such as procedural learning or practice effects.
Adverse effects, either observed or spontaneously reported, were recorded at each visit and classified in terms of onset, duration, severity, action taken, and outcome. Electrocardiogram and laboratory tests, including hematology, and clinical chemistry were performed on admission and at the end of adjunctive treatment.
Statistical Analysis
As this was a pilot study, no formal sample size calculation was performed. Data obtained from the study underwent check and quality control and subsequently to descriptive and inferential statistical analysis. Because of the small sample size, the analyses were carried out by nonparametric tests. An intention-to-treat analysis with last observation carried forward was performed. Continuous data were expressed as mean (SD), and the withingroup differences in efficacy ratings between baseline and final test were analyzed by the Wilcoxon rank sum test. To measure the magnitude of a treatment effect, effect size was provided by using Cohen d statistic and was considered small when lower than 0.50, moderate when ranging from 0.50 to 0.79, and large when equal to or greater than 0.80. The significance level for the test was P < 0.05. The statistical analysis was performed with SPSS 16.0 software (SPSS Inc, Chicago, Ill).
RESULTS
Twenty outpatients, 12 men and 8 women, aged 22 to 65 years, fulfilled inclusion criteria and were eligible for the study. The baseline characteristic, the duration of SRIs prior treatment, SRI type, and daily dose in the OCD group are detailed in Table 1 . Seventeen patients completed the study (85% completion rate); there were 3 premature dropouts: 2 were due to noncompliance with the visits and 1 dropout due to a subjectively assessed lack of efficacy. Table 2 shows the baseline and final scores of the different efficacy measures and the effect size for the sample group.
Concerning clinical symptoms, at week 12 within-group comparison revealed that ziprasidone augmentation of SRIs significantly reduced obsessive and compulsive symptoms, as evidenced by changes on Y-BOCS (obsessions, P = 0.048; compulsions, P = 0.005; total score, P = 0.014) scores at the end of the trial (week 12); effect sizes were moderate in Y-BOCS "compulsions" score and small in all other measures.
At the end of the study, the decrease in the Y-BOCS score in the ziprasidone patients showed a mean reduction of 8.14% (SD, 3.1). Regarding treatment response, 4 subjects (23.5% of the completers) had a reduction between 25% and 34%, which could be defined as partial response, whereas none of the patients had a reduction of 35% or greater in Y-BOCS total score, corresponding to a full response, according to the stages of response proposed by Pallanti and Quercioli 5 ; conversely, 1 patient (5.9% of the completers) worsened on Y-BOCS total score versus baseline.
Regarding cognitive performances, no significant differences were found during the study; effect sizes were small in all cognitive explored dimensions.
The augmentation ziprasidone-SRIs was generally well tolerated. The most common adverse effects were gastrointestinal symptoms (4 patients, 20%) and headache (2 patients, 10%), 
DISCUSSION
The present trial provides the first open-label, uncontrolled trial of ziprasidone added to stable SRI treatment in a sample of OCD patients who have had an incomplete clinical response to SRI treatment. Based on our findings, adjunctive ziprasidone appeared to be mildly effective for reducing clinical symptoms in the study sample. Examining Y-BOCS total score and subscores, ziprasidone was moderately efficacious in reducing compulsive symptoms, whereas a small effect was observed in obsessive and total scores. At the end of the trial, none of the subjects reached a full clinical response (>35% Y-BOCS total score reduction).
Regarding cognitive symptoms, no changes in performances at the neuropsychological tasks were observed during ziprasidone treatment. Ziprasidone add-on was well tolerated at the 80-mg/d dosage, as evidenced by the small number of dropouts in the sample during the 12-week treatment period for causes unrelated to unwanted/adverse events and by the presence of mild and transient adverse effects.
The lack of a good clinical response of ziprasidone augmentation in partial-responder OCD patients is conflicting with previous data. Nevertheless, it should be noticed that only 2 studies have evaluated the efficacy of ziprasidone in treatment-resistant OCD. 20, 21 The first 20 consisted of a case report describing a 56-year-old female patient whose Y-BOCS total score decreased from 32 to 5 after augmentation with ziprasidone at the dose of 40 mg/d. The second 21 was a retrospective study that compared OCD patients treated with adjunctive quetiapine (n = 15) or ziprasidone (n = 9) for 24 weeks. In the quetiapine group, clinical improvement was observed in 80% of patients, whereas only 44.4% of the ziprasidone group improved at the end of the study period; furthermore, Y-BOCS and Clinical Global Impression-Severity mean scores were higher in the ziprasidone group at follow-up. Such descriptive results need to be interpreted with a great deal of caution as case reports and case series do not provide definitive explanations or supply evidence that one treatment is superior to another; thus, no firm conclusions can be drawn from the above data.
As well, the findings of the present study need a careful interpretation because of a number of limitations, such as the small sample size, the lack of a control group, the open design, and fixed, low dose (80 mg/d) of adjunctive ziprasidone. In addition, adverse effects were recorded at each visit by clinical interview, and no formal psychometric measure of extrapyramidal side effects was used.
Despite the limitations, our study suggests that ziprasidone added to ongoing treatment appeared to be mildly effective to improve symptoms in patients with OCD who have failed to respond sufficiently to SRIs. Further studies are needed to identify subgroups of patients with peculiar features, which may account for responsivity to experimental medications, and to clarify the relative efficacy of different add-on treatments in OCD by designing randomized controlled trials aimed to verify which drug augmentation strategies are more beneficial in treatment-resistant OCD patients. 
